Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020).
Ther Adv Cardiovasc Dis
; 16: 17539447221137170, 2022.
Статья
в английский
| MEDLINE | ID: covidwho-2139019
ABSTRACT
BACKGROUND:
Management of high blood pressure (BP) typically requires adherence to medication regimes. However, it is known that the COVID-19 pandemic both interrupted access to some routine prescriptions and changed some patient health behaviours.AIM:
This study, therefore, retrospectively investigated prescription reimbursement of cardiovascular (CVD) medicines as a proxy measure for patient adherence and access to medicines during the pandemic.METHODS:
A cohort study of all primary care patients in England prescribed CVD medicines. The exposure was to the global pandemic. Prescriptions were compared before and after the pandemic's onset. Statistical variation was the outcome of interest.RESULTS:
Descriptive statistics show changes to monthly prescriptions, with wide confidence intervals indicating varying underlying practice. Analysis of variance reveals statistically significant differences for bendroflumethiazide, potassium-sparing diuretics, nicorandil, ezetimibe, ivabradine, ranolazine, colesevelam and midodrine. After the pandemic began (March-October 2020), negative parameters are observed for ACE inhibitors, beta-blockers, calcium channel blockers, statins, antiplatelet, antithrombotics, ARBs, loop diuretics, doxazosin, bendroflumethiazide, nitrates and indapamide, indicating decelerating monthly prescription items (statistically significant declines of calcium channel blockers, antithrombotic, adrenoreceptor blockers and diuretics) of CVD medicines within the general population. Many data points are not statistically significant, but fluctuations remain clinically important for the large population of patients taking these medications.CONCLUSION:
A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available https//bit.ly/39gvEHi.ключевые слова
COVID-19; SARS-CoV-2; analysis of variance; angiotensin II; angiotensin-converting enzyme inhibitors; bendroflumethiazide; calcium channel blockers; cardiovascular diseases; colesevelam hydrochloride; communicable disease control; confidence intervals; delivery of health care; diuretics; doxazosin; ezetimibe; fibrinolytic agents; health services accessibility; health status disparities; heart diseases; hydroxymethylglutaryl-CoA reductase inhibitors; indapamide; interrupted time-series analysis; ivabradine; life expectancy; medication adherence; medicine; midodrine; nicorandil; nitrates; pandemics; pharmacies; potassium sparing; prescriptions; primary health care; ranolazine; retrospective studies; sodium potassium chloride symporter inhibitors
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Cardiovascular Agents
/
Cardiovascular Diseases
/
COVID-19
/
Heart Diseases
Тип исследования:
Когортное исследование
/
Диагностическое исследование
/
Экспериментальные исследования
/
Наблюдательное исследование
/
Прогностическое исследование
Пределы темы:
Люди
Язык:
английский
Журнал:
Ther Adv Cardiovasc Dis
Тематика журнала:
Болезни системы кровообращения
/
Кардиология
/
Терапия
Год:
2022
Тип:
Статья
Аффилированная страна:
17539447221137170
Документы, близкие по теме
MEDLINE
...
LILACS
LIS